Markers with significant change over time (n = 15) in HCT-treated patients with MPS I
Marker . | Slope* . | P . | Pathway . | Differentiating pre-HCT . |
---|---|---|---|---|
CXCL9 | −0.09 | .049 | Pro-inflammatory | Yes |
CXCL10 | −0.12 | .04 | Pro-inflammatory | No |
CCL3 | −0.13 | .01 | Pro-inflammatory | No |
CCL4 | −0.10 | .02 | Pro-inflammatory | Yes |
CCL19 | −0.09 | .03 | Pro-inflammatory | No |
CCL20 | −0.09 | .04 | Pro-inflammatory | No |
CCL25 | −0.08 | .02 | Pro-inflammatory | No |
MCP.3 | −0.07 | .03 | Pro-inflammatory | No |
IFN.γ | −0.12 | .04 | Pro-inflammatory | No |
TNF | −0.07 | .009 | Pro-inflammatory | No |
TNFB | −0.06 | .04 | Pro-inflammatory | No |
TNFRSF9 | −0.08 | .009 | Pro-inflammatory | No |
CDCP1 | −0.06 | .04 | Pro-inflammatory | No |
Flt3L | 0.1 | .03 | Growth factor/bone homeostasis | No |
SCF | 0.1 | .03 | Growth factor/bone homeostasis | Yes |
Marker . | Slope* . | P . | Pathway . | Differentiating pre-HCT . |
---|---|---|---|---|
CXCL9 | −0.09 | .049 | Pro-inflammatory | Yes |
CXCL10 | −0.12 | .04 | Pro-inflammatory | No |
CCL3 | −0.13 | .01 | Pro-inflammatory | No |
CCL4 | −0.10 | .02 | Pro-inflammatory | Yes |
CCL19 | −0.09 | .03 | Pro-inflammatory | No |
CCL20 | −0.09 | .04 | Pro-inflammatory | No |
CCL25 | −0.08 | .02 | Pro-inflammatory | No |
MCP.3 | −0.07 | .03 | Pro-inflammatory | No |
IFN.γ | −0.12 | .04 | Pro-inflammatory | No |
TNF | −0.07 | .009 | Pro-inflammatory | No |
TNFB | −0.06 | .04 | Pro-inflammatory | No |
TNFRSF9 | −0.08 | .009 | Pro-inflammatory | No |
CDCP1 | −0.06 | .04 | Pro-inflammatory | No |
Flt3L | 0.1 | .03 | Growth factor/bone homeostasis | No |
SCF | 0.1 | .03 | Growth factor/bone homeostasis | Yes |
CCL, C-C motif chemokine ligand; CXCL, C-C-C motif chemokine ligand; IFN, interferon; MCP, monocyte chemoattractant protein; SCF, stem cell factor; TNF-a, tumor necrosis factor alpha; TNFRSF, tumor necrosis factor receptor superfamily
The slope of the linear mixed model indicates the change in NPX unit per year.